These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 23496302)

  • 1. Treatment satisfaction in the sensor-augmented pump therapy for A1C reduction 3 (STAR 3) trial.
    Peyrot M; Rubin RR;
    Diabet Med; 2013 Apr; 30(4):464-7. PubMed ID: 23496302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health-related quality of life and treatment satisfaction in the Sensor-Augmented Pump Therapy for A1C Reduction 3 (STAR 3) trial.
    Rubin RR; Peyrot M;
    Diabetes Technol Ther; 2012 Feb; 14(2):143-51. PubMed ID: 22133037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensor-augmented pump therapy lowers HbA(1c) in suboptimally controlled Type 1 diabetes; a randomized controlled trial.
    Hermanides J; Nørgaard K; Bruttomesso D; Mathieu C; Frid A; Dayan CM; Diem P; Fermon C; Wentholt IM; Hoekstra JB; DeVries JH
    Diabet Med; 2011 Oct; 28(10):1158-67. PubMed ID: 21294770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of continuous glucose monitoring on quality of life, treatment satisfaction, and use of medical care resources: analyses from the SWITCH study.
    Hommel E; Olsen B; Battelino T; Conget I; Schütz-Fuhrmann I; Hoogma R; Schierloh U; Sulli N; Gough H; Castañeda J; de Portu S; Bolinder J;
    Acta Diabetol; 2014 Oct; 51(5):845-51. PubMed ID: 25037251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of sensor-augmented pump therapy on glycemic variability in well-controlled type 1 diabetes in the STAR 3 study.
    Buse JB; Kudva YC; Battelino T; Davis SN; Shin J; Welsh JB
    Diabetes Technol Ther; 2012 Jul; 14(7):644-7. PubMed ID: 22524549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month continuation phase.
    Bergenstal RM; Tamborlane WV; Ahmann A; Buse JB; Dailey G; Davis SN; Joyce C; Perkins BA; Welsh JB; Willi SM; Wood MA;
    Diabetes Care; 2011 Nov; 34(11):2403-5. PubMed ID: 21933908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment satisfaction and quality of life for an integrated continuous glucose monitoring/insulin pump system compared to self-monitoring plus an insulin pump.
    Rubin RR; Peyrot M
    J Diabetes Sci Technol; 2009 Nov; 3(6):1402-10. PubMed ID: 20144395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Sensor-Augmented Pump Therapy with Predictive Low-Glucose Suspend Function on Glycemic Control and Patient Satisfaction in Adults and Children with Type 1 Diabetes.
    Beato-Víbora PI; Quirós-López C; Lázaro-Martín L; Martín-Frías M; Barrio-Castellanos R; Gil-Poch E; Arroyo-Díez FJ; Giménez-Álvarez M
    Diabetes Technol Ther; 2018 Nov; 20(11):738-743. PubMed ID: 30256132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The SWITCH study (sensing with insulin pump therapy to control HbA(1c)): design and methods of a randomized controlled crossover trial on sensor-augmented insulin pump efficacy in type 1 diabetes suboptimally controlled with pump therapy.
    Conget I; Battelino T; Giménez M; Gough H; Castañeda J; Bolinder J;
    Diabetes Technol Ther; 2011 Jan; 13(1):49-54. PubMed ID: 21175271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of sensor-augmented pump therapy in children and adolescents with type 1 diabetes in the STAR 3 study.
    Slover RH; Welsh JB; Criego A; Weinzimer SA; Willi SM; Wood MA; Tamborlane WV
    Pediatr Diabetes; 2012 Feb; 13(1):6-11. PubMed ID: 21722284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. STAR 3 randomized controlled trial to compare sensor-augmented insulin pump therapy with multiple daily injections in the treatment of type 1 diabetes: research design, methods, and baseline characteristics of enrolled subjects.
    Davis SN; Horton ES; Battelino T; Rubin RR; Schulman KA; Tamborlane WV
    Diabetes Technol Ther; 2010 Apr; 12(4):249-55. PubMed ID: 20210562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recovery of hypoglycemia awareness in long-standing type 1 diabetes: a multicenter 2 × 2 factorial randomized controlled trial comparing insulin pump with multiple daily injections and continuous with conventional glucose self-monitoring (HypoCOMPaSS).
    Little SA; Leelarathna L; Walkinshaw E; Tan HK; Chapple O; Lubina-Solomon A; Chadwick TJ; Barendse S; Stocken DD; Brennand C; Marshall SM; Wood R; Speight J; Kerr D; Flanagan D; Heller SR; Evans ML; Shaw JA
    Diabetes Care; 2014 Aug; 37(8):2114-22. PubMed ID: 24854041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Threshold-based insulin-pump interruption for reduction of hypoglycemia.
    Bergenstal RM; Klonoff DC; Garg SK; Bode BW; Meredith M; Slover RH; Ahmann AJ; Welsh JB; Lee SW; Kaufman FR;
    N Engl J Med; 2013 Jul; 369(3):224-32. PubMed ID: 23789889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Closing the Loop in Adults, Children and Adolescents With Suboptimally Controlled Type 1 Diabetes Under Free Living Conditions: A Psychosocial Substudy.
    Barnard KD; Wysocki T; Ully V; Mader JK; Pieber TR; Thabit H; Tauschmann M; Leelarathna L; Hartnell S; Acerini CL; Wilinska ME; Dellweg S; Benesch C; Arnolds S; Holzer M; Kojzar H; Campbell F; Yong J; Pichierri J; Hindmarsh P; Heinemann L; Evans ML; Hovorka R
    J Diabetes Sci Technol; 2017 Nov; 11(6):1080-1088. PubMed ID: 28367636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: the RealTrend study.
    Raccah D; Sulmont V; Reznik Y; Guerci B; Renard E; Hanaire H; Jeandidier N; Nicolino M
    Diabetes Care; 2009 Dec; 32(12):2245-50. PubMed ID: 19767384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of flash glucose monitoring on hypoglycaemia in adults with type 1 diabetes managed with multiple daily injection therapy: a pre-specified subgroup analysis of the IMPACT randomised controlled trial.
    Oskarsson P; Antuna R; Geelhoed-Duijvestijn P; Krӧger J; Weitgasser R; Bolinder J
    Diabetologia; 2018 Mar; 61(3):539-550. PubMed ID: 29273897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing the effectiveness of a 3-month day-and-night home closed-loop control combined with pump suspend feature compared with sensor-augmented pump therapy in youths and adults with suboptimally controlled type 1 diabetes: a randomised parallel study protocol.
    Bally L; Thabit H; Tauschmann M; Allen JM; Hartnell S; Wilinska ME; Exall J; Huegel V; Sibayan J; Borgman S; Cheng P; Blackburn M; Lawton J; Elleri D; Leelarathna L; Acerini CL; Campbell F; Shah VN; Criego A; Evans ML; Dunger DB; Kollman C; Bergenstal RM; Hovorka R
    BMJ Open; 2017 Jul; 7(7):e016738. PubMed ID: 28710224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin pump therapy: impact on the lives of children/young people with diabetes mellitus and their parents.
    Alsaleh FM; Smith FJ; Thompson R; Al-Saleh MA; Taylor KM
    Int J Clin Pharm; 2014 Oct; 36(5):1023-30. PubMed ID: 25108411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perceptions in Type 1 Diabetes Mellitus with or Without the Use of Insulin Pump: An Online Study.
    Benioudakis ES
    Curr Diabetes Rev; 2020; 16(8):874-880. PubMed ID: 31057119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unsupervised home use of an overnight closed-loop system over 3-4 weeks: a pooled analysis of randomized controlled studies in adults and adolescents with type 1 diabetes.
    Thabit H; Elleri D; Leelarathna L; Allen JM; Lubina-Solomon A; Stadler M; Walkinshaw E; Iqbal A; Choudhary P; Wilinska ME; Barnard KD; Heller SR; Amiel SA; Evans ML; Dunger DB; Hovorka R
    Diabetes Obes Metab; 2015 May; 17(5):452-8. PubMed ID: 25492378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.